EGFR and non-small cell lung carcinoma: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib (Iressa®) [9] have proven to be effective in the treatment of patients with advanced NSCLC harboring these EGFR mutations.